Regenerative Therapy is a premier open-access journal dedicated to advancing the fields of biomaterials, biomedical engineering, and developmental biology. Published by Elsevier in Japan, this journal has been an influential platform since its inception in 2015, contributing significantly to the global discourse on regenerative medicine. With an impressive Q2 ranking in major categories such as Biomaterials and Biomedical Engineering, it is recognized for its quality of research and innovation. Researchers seeking to disseminate their findings or explore cutting-edge developments will find Regenerative Therapy to be invaluable, reflecting current trends and fostering collaborations across interdisciplinary boundaries. The journal offers open access, ensuring that high-quality research is available to a broad audience and enhances the impact of scholarly work in the regenerative medicine community.

Stem Cells and Cloning-Advances and Applications is a leading peer-reviewed journal dedicated to the dynamic fields of stem cell research and cloning technologies. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this Open Access journal ensures that groundbreaking findings are accessible to a global audience. With a focus on innovative applications and advancements in cellular biology, the journal plays a pivotal role in disseminating knowledge within the scientific community. The journal currently holds an impact factor that reflects its influence, with notable rankings in both Cell Biology and Medicine (Miscellaneous), showcasing its interdisciplinary relevance. Researchers, professionals, and students alike benefit from the journal’s wide-ranging contributions, covering critical topics from regenerative medicine to genetic research. With a commitment to fostering collaboration and encouraging discussion in these cutting-edge domains, Stem Cells and Cloning-Advances and Applications continues to be a vital resource for advancing scientific inquiry and application.

Acta Biomaterialia, published by Elsevier Science Ltd, is a leading journal in the fields of biochemistry, biomaterials, biomedical engineering, biotechnology, and molecular biology. With an ISSN of 1742-7061 and an E-ISSN of 1878-7568, this prestigious journal has secured a remarkable position in the academic community, evidenced by its inclusion in the Q1 category across multiple disciplines for 2023. It ranks impressively at #21 in biochemistry, #16 in biomedical engineering, #18 in biotechnology, and #11 in biomaterials, reflecting its high impact and relevance to ongoing research and development. The journal provides a platform for disseminating innovative research and advancements in the design and application of biomaterials, contributing to scientific discussions that propel the field forward. Although it does not currently offer open access options, Acta Biomaterialia continues to attract contributions that advance our understanding of biomaterials and their interactions with biological systems, ensuring that researchers, professionals, and students remain informed about the latest trends and breakthroughs in this rapidly evolving area of study.

Stem Cells International is a premier open access journal published by HINDAWI LTD, focusing on the rapidly evolving field of stem cell research. With an ISSN of 1687-966X and E-ISSN 1687-9678, this journal has been a vital resource since its inception in 2010, showcasing innovative studies and breakthroughs up to 2024. Positioned in Q3 in Cell Biology and Q2 in Molecular Biology for 2023, as well as well-ranked in the Scopus database, the journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the implications of stem cell technology in regenerative medicine and biological research. The open access model ensures wide accessibility, fostering collaboration and knowledge-sharing across the scientific community, making it a cornerstone in advancing the understanding and application of stem cell science.

The International Journal of Bioprinting, published by Accscience Publishing, is a pioneering platform dedicated to advancing the field of bioprinting and its applications in biotechnology and manufacturing engineering. Established in 2015, this journal has quickly gained recognition, reflected in its prestigious placements within the Q1 and Q2 quartiles across various categories, including Industrial and Manufacturing Engineering, Biotechnology, and Materials Science. With *Scopus rankings* placing it in the top percentiles of its respective fields, the journal aims to provide researchers, professionals, and students with cutting-edge insights and innovative methodologies that drive the evolution of bioprinting technologies. The International Journal of Bioprinting not only facilitates access to high-quality, peer-reviewed research articles but also supports the rapidly growing community dedicated to the exploration of bioprinting applications, making it an essential resource for those on the forefront of this exciting scientific frontier.

Tissue Engineering Part C: Methods is a prestigious academic journal published by MARY ANN LIEBERT, INC, specializing in the dynamic and rapidly evolving fields of bioengineering and biomedical engineering. With an ISSN of 1937-3384 and E-ISSN 1937-3392, this journal provides a platform for the dissemination of cutting-edge research from 2008 to 2024, showcasing methodologies that advance the science of tissue engineering. Ranked in the second and third quartiles across several categories in 2023, including a notable Q2 in Biomedical Engineering, the journal is recognized for its contributions to the interface of biology and engineering. Additionally, it holds commendable Scopus ranks that highlight its influence and reach within the scientific community. Although it does not offer open access, the journal remains vital for researchers, professionals, and students seeking insightful articles that bridge the gap between theoretical research and practical application in tissues and regenerative medicine. With its rigorous peer-review process and commitment to quality, Tissue Engineering Part C: Methods continues to be an essential resource for those at the forefront of tissue engineering innovations.

Regenerative Medicine, published by Taylor & Francis Ltd, is a pivotal journal within the field of biomedical research, focusing on the innovative advances in regenerative and restored functions in human health. With an ISSN of 1746-0751 and an E-ISSN of 1746-076X, this esteemed journal boasts a commendable impact factor within its categories, notably holding the Q2 status in Embryology and Q3 in Biomedical Engineering as of 2023. Covering a broad spectrum of topics from stem cell research to tissue engineering, it serves as a crucial platform for interdisciplinary collaboration among researchers, professionals, and students dedicated to the regeneration of tissues and organs. Given its comprehensive scope from 2006 to 2024, the journal continues to attract high-quality manuscripts that advance the frontiers of knowledge in regenerative medicine. Researchers and practitioners alike are encouraged to engage with the latest findings and methodologies disseminated in this vital publication.

Biomedical Materials, published by IOP Publishing Ltd, is a premier journal dedicated to the rapidly evolving field of biomedical engineering and materials science. With a robust impact factor showcasing its influence, this journal serves as a vital platform for disseminating pioneering research from 2006 to 2024. Covering an array of interdisciplinary topics—ranging from biomaterials to bioengineering and applied chemistry—the journal consistently ranks in the second quartile across multiple categories including Bioengineering (Q2), Biomaterials (Q2), and Biomedical Engineering (Q2) as of 2023. Researchers, professionals, and students alike benefit from its contributions, exploring innovative solutions at the intersection of biology and material science. Although not an Open Access journal, Biomedical Materials remains essential in advancing our understanding and facilitating discussions surrounding state-of-the-art materials that revolutionize medical applications and enhance patient care.

Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.